Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection
- PMID: 11359807
- DOI: 10.4049/jimmunol.166.11.6555
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection
Abstract
Low-frequency CTL and low-titer IgM responses against tumor-associated Ag MUC1 are present in cancer patients but do not prevent cancer growth. Boosting MUC1-specific immunity with vaccines, especially effector mechanisms responsible for tumor rejection, is an important goal. We studied immunogenicity, tumor rejection potential, and safety of three vaccines: 1) MUC1 peptide admixed with murine GM-CSF as an adjuvant; 2) MUC1 peptide admixed with adjuvant SB-AS2; and 3) MUC1 peptide-pulsed dendritic cells (DC). We examined the qualitative and quantitative differences in humoral and T cell-mediated MUC1-specific immunity elicited in human MUC1-transgenic (Tg) mice compared with wild-type (WT) mice. Adjuvant-based vaccines induced MUC1-specific Abs but failed to stimulate MUC1-specific T cells. MUC1 peptide with GM-CSF induced IgG1 and IgG2b in WT mice but only IgM in MUC1-Tg mice. MUC1 peptide with SB-AS2 induced high-titer IgG1, IgG2b, and IgG3 Abs in both WT and MUC1-Tg mice. Induction of IgG responses was T cell independent and did not have any effect on tumor growth. MUC1 peptide-loaded DC induced only T cell immunity. If injected together with soluble peptide, the DC vaccine also triggered Ab production. Importantly, the DC vaccine elicited tumor rejection responses in both WT and MUC1-Tg mice. These responses correlated with the induction of MUC1-specific CD4+ and CD8+ T cells in WT mice, but only CD8(+) T cells in MUC1-Tg mice. Even though MUC1-specific CD4+ T cell tolerance was not broken, the capacity of MUC1-Tg mice to reject tumor was not compromised.
Similar articles
-
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.Cancer Res. 2010 Jul 15;70(14):5788-96. doi: 10.1158/0008-5472.CAN-09-4519. Epub 2010 Jun 29. Cancer Res. 2010. PMID: 20587526 Free PMC article.
-
T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.Int Immunopharmacol. 2005 Feb;5(2):315-30. doi: 10.1016/j.intimp.2004.10.004. Int Immunopharmacol. 2005. PMID: 15652762
-
Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.J Immunol. 2002 Jun 15;168(12):6099-105. doi: 10.4049/jimmunol.168.12.6099. J Immunol. 2002. PMID: 12055220
-
TG4010: a vaccine with a therapeutic role in cancer.Immunotherapy. 2016 May;8(5):511-9. doi: 10.2217/imt-2016-0015. Immunotherapy. 2016. PMID: 27140406 Review.
-
Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.Curr Protein Pept Sci. 2006 Aug;7(4):307-15. doi: 10.2174/138920306778018034. Curr Protein Pept Sci. 2006. PMID: 16918445 Review.
Cited by
-
Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.Blood. 2005 Aug 1;106(3):963-70. doi: 10.1182/blood-2005-01-0201. Epub 2005 Apr 7. Blood. 2005. PMID: 15817683 Free PMC article.
-
Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.Semin Immunol. 2020 Feb;47:101389. doi: 10.1016/j.smim.2020.101389. Epub 2020 Jan 9. Semin Immunol. 2020. PMID: 31926647 Free PMC article. Review.
-
Genetically engineered mucin mouse models for inflammation and cancer.Cancer Metastasis Rev. 2015 Dec;34(4):593-609. doi: 10.1007/s10555-015-9549-1. Cancer Metastasis Rev. 2015. PMID: 25634251 Free PMC article. Review.
-
Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies.Cancers (Basel). 2022 Dec 26;15(1):138. doi: 10.3390/cancers15010138. Cancers (Basel). 2022. PMID: 36612133 Free PMC article. Review.
-
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.Biol Chem. 2009 Jul;390(7):611-8. doi: 10.1515/BC.2009.070. Biol Chem. 2009. PMID: 19426130 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous